Sagimet Biosciences Inc. cash flow to debt ratio of -58.53K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Sagimet Biosciences Inc.'s free cash flow has decreased 7.58% from $-42.44M last year to $-45.65M, signaling decreasing performance

Sagimet Biosciences Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Sagimet Biosciences Inc.'s debt has increased relative to shareholder equity from 0.00 last year to 0.01 today, signaling weakened financials

Sagimet Biosciences Inc. has a net cash position, so leverage is healthy.

Sagimet Biosciences Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Sagimet Biosciences Inc. has insufficient data to evaluate this check.

Sagimet Biosciences Inc.'s short-term assets of $116.40M exceed its short-term liabilities of $5.10M

Sagimet Biosciences Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Sagimet Biosciences Inc.'s return on equity of -31.96%, is lower than 15.00%, indicating bad performance

Sagimet Biosciences Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Sagimet Biosciences Inc. has insufficient public price history to evaluate earnings stability.

Sagimet Biosciences Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Sagimet Biosciences Inc. has negative free cash flow, indicating cash burn

Sagimet Biosciences Inc.'s yearly earnings has decreased 12.01% since last year from $-45.57M to $-51.04M, signaling decreasing performance

Sagimet Biosciences Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -20.39% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Sagimet Biosciences Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Sagimet Biosciences Inc. has insufficient public price history to evaluate revenue consistency.

Sagimet Biosciences Inc. has insufficient public price history to evaluate ROE consistency.

Sagimet Biosciences Inc. has insufficient data to evaluate this check.

Sagimet Biosciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sagimet Biosciences Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Sagimet Biosciences Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Sagimet Biosciences Inc. has insufficient data to evaluate this check.

Sagimet Biosciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sagimet Biosciences Inc. has a price-to-book ratio of 1.98x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Sagimet Biosciences Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue